# Damien Urban

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/damien-urban/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,563 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 26 |
| i10-index | 42 |
| Last Known Institution | Tel Aviv University |
| OpenAlex ID | https://openalex.org/A5010090678 |
| ORCID iD | 0000-0002-9143-751X |
| Works | 139 |

## Researcher papers

- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)
- [BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors](https://scholariq.org/papers/braf-mutant-lung-cancer-programmed-death-ligand-1-expression-tumor-mutational/)
- [Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma](https://scholariq.org/papers/prognostic-significance-of-pd-l1-and-cd8-immune-cells-in-hpv-oropharyngeal/)
- [Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study](https://scholariq.org/papers/subcutaneous-versus-intravenous-amivantamab-both-in-combination-with-lazertinib/)
- [Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study](https://scholariq.org/papers/acute-vascular-events-as-a-possibly-related-adverse-event-of-immunotherapy-a/)
- [Frequency and prognostic significance of p16INK4A protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma](https://scholariq.org/papers/frequency-and-prognostic-significance-of-p16ink4a-protein-overexpression-and/)
- [Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/lymph-node-ratio-may-predict-the-benefit-of-postoperative-radiotherapy-in-non/)
- [Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience](https://scholariq.org/papers/patterns-of-use-of-medical-cannabis-among-israeli-cancer-patients-a-single/)
- [Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities](https://scholariq.org/papers/cancer-of-unknown-primary-a-population-based-analysis-of-temporal-change-and/)
- [Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data](https://scholariq.org/papers/pembrolizumab-as-a-monotherapy-or-in-combination-with-platinum-based/)
- [Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer](https://scholariq.org/papers/transformation-to-small-cell-lung-cancer-as-a-mechanism-of-resistance-to/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [Tel Aviv University](https://scholariq.org/institutions/tel-aviv-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.